

Developing Countries Vaccine Manufacturers Network

## DCVMN COVID-19 Committee

SURVEY FINDINGS AND NEXT STEPS



### Survey objectives

1) Evaluate the effectiveness of the committee in achieving its objectives

2) Gather descriptive feedback from committee members and observers

3) Identify gaps/weaknesses of committee meetings and/or objectives

4) Facilitate discussion among members and observers

 $\rightarrow$  realign objectives, committee organization and workplan




### Survey respondents


#### 7 anonymous responses to the survey:

Has your organization been engaged in COVID-19 vaccine development

Has your organization been engaging in a tech transfer, licensing agreement or joint venture to manufacturer COVID-19 vaccines?



## The objectives of the COVID-19 committee








# The objectives of the COVID-19 committee (aggregate scores)

Discussing solutions provided by organizations	18	
Evaluating prime COVID-19 vaccine candidates	19	
Discussing and evaluating technical information	20	
Assessing and sharing information on technologies		21
Developing solid bases for statements to support DCVMN dialogue		21



### Qualitative insights - Benefits



- Provides geographic overview of COVID-19 vaccines and players
- Opportunity to share experiences from different companies and countries
- Learning from each other + share best practices

- No impact on the decisions made by stakeholders
- Members are not aware of the actions being taken by the network (or elected network members) in various forums.
- The committee was formed to formulate opinions (on topics such vaccine distribution) and circulate them to stakeholders. This has not been effectively undertaken or communicated



## Qualitative insights – What needs to be addressed

	Epidemiological updates (variants)	1
Topics mentioned by respondents	Vaccine distribution	1
	Funding opportunties	1
	Analytical methods	1
	Pharmacovigilance	1
	Platform technologies and tech transfers	2
	Regulatory requirements	2
Vacci	ne landscape (incl. those for variants) + next gen vaccines	3
	Clinical Trials and efficacy studies of registered vaccines	3
		Frequency

## Qualitative insights – challenges faced Developing Countries Vaccine in introducing COVID-19 vaccine product

#### Funding

- Internal development
- For 'at risk' manufacturing prior to licensure
- Adjuvant access

#### **Regulatory hurdles**

- Government regulations
- NRAs regulations not fit to pandemic situation
- Regulation standards of new production processes

#### **Up-scaling**

- Scaling up manufacturing
- Implementing new production processes



# Committee meetings: efficiency & frequency

Are meetings conducted in a clear and efficient manner



"Difficult to answer"

"More like coffee corner talk than a meeting"

"In the initial meetings, only the obvious and rampant information from the media was discussed. We did not think about actual objectives".

Preferred frequency of committee				
meetings				

Quarterly	2	
Monthly		5

"Depends on the quality"



### Additional comments

"Surveys like this are really very important for us to try to rescue Committee members who, over time, ended up not prioritizing their participation in the Committee. Perhaps by bringing more attractive subjects to the Committee's agenda, these members will be more interested in participating".

"We need to have meetings involving various working groups in the DCVMN. Each working group has a key role to play during this pandemic. The more minds we can involve the better".

"COVID-19 is very broad topic. It is quite difficult to expect to cover all aspects. All members have their own work and cannot fully focus".